Alireza Heidari

Faculty of Chemistry

California South University (CSU), USA




2009–2012 Ph.D., Faculty of Chemistry, California South University, California, USA

2006–2008 M.Sc., Faculty of Chemistry, Islamic Azad University (IAU), North Tehran Branch, Tehran, Iran

2001–2005 B.Sc., Faculty of Chemistry, Islamic Azad University (IAU), North Tehran Branch, Tehran, Iran

Publications (selected)

  1. A. Heidari, “Chemotherapy a last resort for cancer treatment”, Chemo Open Access 5: 4, 2016.
  2. A. Heidari, “Separation and pre–concentration of metal cations–DNA/RNA chelates using molecular beam mass spectrometry with tunable vacuum ultraviolet (VUV) synchrotron radiation and various analytical methods”, Mass Spectrom Purif Tech 2: e101, 2016.
  3. A. Heidari, “Yoctosecond quantitative structure–activity relationship (QSAR) and quantitative structure–property relationship (QSPR) under synchrotron radiations studies for prediction of solubility of anti–cancer nano drugs in aqueous solutions using genetic function approximation (GFA) algorithm”, Insight Pharm Res. 1: 1, 2016.
  4. A. Heidari, “Cancer risk prediction and assessment in human cells under synchrotron radiations using quantitative structure activity relationship (QSAR) and quantitative structure properties relationship (QSPR) studies”, Int J Clin Med Imaging 3: 516, 2016.
  5. A. Heidari, “A novel approach to biology”, Electronic J Biol 12: 4, 2016.
  6. A. Heidari, “Innovative biomedical equipment’s for diagnosis and treatment”, J Bioengineer & Biomedical Sci 6: 2, 2016.
  7. A. Heidari, “Integrating precision cancer medicine into healthcare, medicare reimbursement changes and the practice of oncology: Trends in oncology medicine and practices”, J Oncol Med & Pract 1: 2, 2016.13
  8. A. Heidari, “Promoting convergence in biomedical and biomaterials sciences and silk proteins for biomedical and biomaterials applications: An introduction to materials in medicine and bioengineering perspectives”, J Bioengineer & Biomedical Sci 6: 3, 2016.
  9. A. Heidari, “X–ray fluorescence and x–ray diffraction analysis on discrete element modeling of nano powder metallurgy processes in optimal container design”, J Powder Metall Min 6: 1, 2017.
  10. A. Heidari, “Biomolecular spectroscopy and dynamics of nano–sized molecules and clusters as cross–linking–induced anti–cancer and immune–oncology nano drugs delivery in DNA/RNA of uuman cancer cells’ membranes under synchrotron radiations: A payload–based perspective”, Arch Chem Res. 1: 2, 2017.
  11. A. Heidari, “Deficiencies in repair of double–standard DNA/RNA–binding molecules identified in many types of solid and liquid tumors oncology in human body for advancing cancer immunotherapy using computer simulations and data analysis”, J Appl Bioinforma Comput Biol, 6: 1, 2017.
  12. A. Heidari, “Electronic coupling among the five nanomolecules shuts down quantum tunneling in the presence and absence of an applied magnetic field for indication of the dimer or other provide different influences on the magnetic behavior of single molecular magnets (SMMs) as qubits for quantum computing”, Glob J Res Rev. 4: 2, 2017.
  13. A. Heidari, “Polymorphism in nano–sized graphene ligand–induced transformation of Au38–xAgx/xCux(SPh–tBu)24 to Au36–xAgx/xCux(SPh–tBu)24 (x = 1–12) nanomolecules for synthesis of Au144–xAgx/xCux[(SR)60, (SC4)60, (SC6)60, (SC12)60, (PET)60, (p–MBA)60, (F)60, (Cl)60, (Br)60, (I)60, (At)60, (Uus)60 and (SC6H13)60] nano clusters as anti–cancer nano drugs”, J Nanomater Mol Nanotechnol, 6: 3, 2017.
  14. A. Heidari, “Biomedical resource oncology and data mining to enable resource discovery in medical, medicinal, clinical, pharmaceutical, chemical and translational research and their applications in cancer research”, Int J Biomed Data Min 6: e103, 2017.
  15. A. Heidari, “Study of synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy of olympiadane nanomolecules as agent for cancer enzymotherapy, immunotherapy, chemotherapy, radiotherapy, hormone therapy and targeted therapy under synchrotorn radiation”, J Dev Drugs 6: e154, 2017.
  16. A. Heidari, “A Novel approach to future horizon of top seven biomedical research topics to watch in 2017: Alzheimer's, ebola, hypersomnia, human immunodeficiency virus (HIV), tuberculosis (TB), microbiome/antibiotic resistance and endovascular stroke”, J Bioengineer & Biomedical Sci 7: e127, 2017.
  17. A. Heidari, “Opinion on computational fluid dynamics (CFD) technique”, Fluid Mech Open Acc 4: 157, 2017.
  18. A. Heidari, “Concurrent diagnosis of oncology influence outcomes in emergency general surgery for colorectal cancer and multiple sclerosis (MS) treatment using magnetic resonance imaging (MRI) and Au329(SR)84, Au329–xAgx(SR)84, Au144(SR)60, Au68(SR)36, Au30(SR)18, Au102(SPh)44, Au38(SPh)24, Au38(SC2H4Ph)24, Au21S(SAdm)15, 14, Au36(pMBA)24 and Au25(pMBA)18 nano clusters”, J Surgery Emerg Med 1: 21, 2017.
  19. A. Heidari, “Developmental cell biology in adult stem cells death and autophagy to trigger a preventive allergic reaction to common airborne allergens under synchrotron radiation using nanotechnology for therapeutic goals in particular allergy shots (immunotherapy)”, Cell Biol (Henderson, NV) 6: 1, 2017.
  20. A. Heidari, “Changing metal powder characteristics for elimination of the heavy metals toxicity and diseases in disruption of extracellular matrix (ECM) proteins adjustment in cancer metastases induced by osteosarcoma, chondrosarcoma, carcinoid, carcinoma, Ewing’s sarcoma, fibrosarcoma and secondary hematopoietic solid or soft tissue tumors”, J Powder Metall Min 6: 170, 2017.
  21. A. Heidari, “Nanomedicine–based combination anti–cancer therapy between nucleic acids and anti–cancer nano drugs in covalent nano drugs delivery systems for selective imaging and treatment of human brain tumors using hyaluronic acid, alguronic acid and sodium hyaluronate as anti–cancer nano drugs and nucleic acids delivery under synchrotron radiation”, Am J Drug Deliv 5: 2, 2017.
  22. A. Heidari, “Clinical trials of dendritic cell therapies for cancer exposing vulnerabilities in human cancer cells’ metabolism and metabolomics: New discoveries, unique features inform new therapeutic opportunities, biotech's bumpy road to the market and elucidating the biochemical programs that support cancer initiation and progression”, J Biol Med Science 1: e103, 2017.
  23. A. Heidari, “The design graphene–based nanosheets as a new nanomaterial in anti–cancer therapy and delivery of chemotherapeutics and biological nano drugs for liposomal anti–cancer nano drugs and gene delivery”, Br Biomed Bull 5: 305, 2017.
  24. A. Heidari, “Integrative approach to biological networks for emerging roles of proteomics, genomics and transcriptomics in the discovery and validation of human colorectal cancer biomarkers from DNA/RNA sequencing data under synchrotron radiation”, Transcriptomics 5: e117, 2017.
  25. A. Heidari, “Elimination of the heavy metals toxicity and diseases in disruption of extracellular matrix (ECM) proteins and cell adhesion intelligent nanomolecules adjustment in cancer metastases using metalloenzymes and under synchrotron radiation”, Lett Health Biol Sci 2 (2): 1–4, 2017.